TRACO Course Evaluation

In order to improve TRACO in future years we would appreciate your feedback on the following course evaluation. Please rank questions (1-28 on a scale of 1 to 5 where 1 is poor and 5 is excellent. Please type any comments that you have on questions (29-31).

OMB No: 0925-0642

Expiration Date: 03/31/2026

Public reporting burden for this collection of information is estimated to average 10 minutes. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate to any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0642). Do not return the completed form to this address.

This survey is optional and you can exit at any time.

Question Title

* 1. Please rank on a scale of 1 to 5 where 1 is poor and 5 is excellent.

	Poor				Excellent
Overall evaluation of course	Overall evaluation of course Poor	Overall evaluation of course	Overall evaluation of course	Overall evaluation of course	Overall evaluation of course Excellent
Course coordination	Course coordination Poor	Course coordination	Course coordination	Course coordination	Course coordination Excellent
“Introduction” Moody	“Introduction” Moody Poor	“Introduction” Moody	“Introduction” Moody	“Introduction” Moody	“Introduction” Moody Excellent
“Immune checkpoints” Goff	“Immune checkpoints” Goff Poor	“Immune checkpoints” Goff	“Immune checkpoints” Goff	“Immune checkpoints” Goff	“Immune checkpoints” Goff Excellent
“HIV” Maldarelli	“HIV” Maldarelli Poor	“HIV” Maldarelli	“HIV” Maldarelli	“HIV” Maldarelli	“HIV” Maldarelli Excellent
”Cervical cancer” Schiller	”Cervical cancer” Schiller Poor	”Cervical cancer” Schiller	”Cervical cancer” Schiller	”Cervical cancer” Schiller	”Cervical cancer” Schiller Excellent
“Global Health” Gopal	“Global Health” Gopal Poor	“Global Health” Gopal	“Global Health” Gopal	“Global Health” Gopal	“Global Health” Gopal Excellent
“Epigenetics” Verma	“Epigenetics” Verma Poor	“Epigenetics” Verma	“Epigenetics” Verma	“Epigenetics” Verma	“Epigenetics” Verma Excellent
“Clinical trials” Smith	“Clinical trials” Smith Poor	“Clinical trials” Smith	“Clinical trials” Smith	“Clinical trials” Smith	“Clinical trials” Smith Excellent
“Microbiota” Greten	“Microbiota” Greten Poor	“Microbiota” Greten	“Microbiota” Greten	“Microbiota” Greten	“Microbiota” Greten Excellent
“Cancer disparities” Ambs	“Cancer disparities” Ambs Poor	“Cancer disparities” Ambs	“Cancer disparities” Ambs	“Cancer disparities” Ambs	“Cancer disparities” Ambs Excellent
“Small molecules” Simeonov	“Small molecules” Simeonov Poor	“Small molecules” Simeonov	“Small molecules” Simeonov	“Small molecules” Simeonov	“Small molecules” Simeonov Excellent
“Ovarian cancer” Lee	“Ovarian cancer” Lee Poor	“Ovarian cancer” Lee	“Ovarian cancer” Lee	“Ovarian cancer” Lee	“Ovarian cancer” Lee Excellent
“Prostate cancer” Karzai	“Prostate cancer” Karzai Poor	“Prostate cancer” Karzai	“Prostate cancer” Karzai	“Prostate cancer” Karzai	“Prostate cancer” Karzai Excellent
“Radiation oncology” Nichols	“Radiation oncology” Nichols Poor	“Radiation oncology” Nichols	“Radiation oncology” Nichols	“Radiation oncology” Nichols	“Radiation oncology” Nichols Excellent
“Tumor imaging” Choyke	“Tumor imaging” Choyke Poor	“Tumor imaging” Choyke	“Tumor imaging” Choyke	“Tumor imaging” Choyke	“Tumor imaging” Choyke Excellent
”Breast cancer”, Zia	”Breast cancer”, Zia Poor	”Breast cancer”, Zia	”Breast cancer”, Zia	”Breast cancer”, Zia	”Breast cancer”, Zia Excellent
“NSCLC” Szabo	“NSCLC” Szabo Poor	“NSCLC” Szabo	“NSCLC” Szabo	“NSCLC” Szabo	“NSCLC” Szabo Excellent
“Genomics” Wei	“Genomics” Wei Poor	“Genomics” Wei	“Genomics” Wei	“Genomics” Wei	“Genomics” Wei Excellent
“Cannabinoids” Freedman	“Cannabinoids” Freedman Poor	“Cannabinoids” Freedman	“Cannabinoids” Freedman	“Cannabinoids” Freedman	“Cannabinoids” Freedman Excellent
"Precision medicine” Harris	"Precision medicine” Harris Poor	"Precision medicine” Harris	"Precision medicine” Harris	"Precision medicine” Harris	"Precision medicine” Harris Excellent
"Nanotechnology" Dobrovolskaia	"Nanotechnology" Dobrovolskaia Poor	"Nanotechnology" Dobrovolskaia	"Nanotechnology" Dobrovolskaia	"Nanotechnology" Dobrovolskaia	"Nanotechnology" Dobrovolskaia Excellent
“Case reports” Olaku	“Case reports” Olaku Poor	“Case reports” Olaku	“Case reports” Olaku	“Case reports” Olaku	“Case reports” Olaku Excellent
“CAR T-cells"Silbert	“CAR T-cells"Silbert Poor	“CAR T-cells"Silbert	“CAR T-cells"Silbert	“CAR T-cells"Silbert	“CAR T-cells"Silbert Excellent
“Liquid biopsy” Ossandon	“Liquid biopsy” Ossandon Poor	“Liquid biopsy” Ossandon	“Liquid biopsy” Ossandon	“Liquid biopsy” Ossandon	“Liquid biopsy” Ossandon Excellent
“Pancreatic cancer”, Alewine	“Pancreatic cancer”, Alewine Poor	“Pancreatic cancer”, Alewine	“Pancreatic cancer”, Alewine	“Pancreatic cancer”, Alewine	“Pancreatic cancer”, Alewine Excellent
“Topoisomerase” Pommier	“Topoisomerase” Pommier Poor	“Topoisomerase” Pommier	“Topoisomerase” Pommier	“Topoisomerase” Pommier	“Topoisomerase” Pommier Excellent
“K-RAS” Luo	“K-RAS” Luo Poor	“K-RAS” Luo	“K-RAS” Luo	“K-RAS” Luo	“K-RAS” Luo Excellent

TRACO Course Evaluation

Question Title

* 1. Please rank on a scale of 1 to 5 where 1 is poor and 5 is excellent.

Question Title

* 2. What were the strengths of the course?

Question Title

* 3. What were the weaknesses of the course?

Question Title

* 4. Suggestions for improvement or other comments.